Aptar and Aceso move inhaled ACT-101 RNA therapy toward clinical development in cystic fibrosis
Aptar Pharma’s Nanopharm will develop the formulation and inhalation strategy for Aceso Therapeutics’ preclinical ACT-101 antisense drug, which aims to stabilize CFTR mRNA rather than edit DNA.
